What are the Amyloid Imaging Taskforce (AIT) guidelines for the use of amyloid beta PET imaging in the diagnosis of Alzheimer disease (AD)?

Updated: May 09, 2019
  • Author: Shaheen E Lakhan, MD, PhD, MS, MEd; Chief Editor: Jasvinder Chawla, MD, MBA  more...
  • Print

The Amyloid Imaging Taskforce (AIT), an assembly of experts from the Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging (SNMMI), developed guidelines for the use of amyloid β (Aβ) positron emission tomography (PET) imaging to clarify diagnoses of AD or frontotemporal dementia. The guidelines outline 3 scenarios in which determining amyloid positivity or negativity would increase the level of diagnostic certainty and alter patient management.

According to the guidelines, amyloid imaging is appropriate in patients with persistent or progressive unexplained mild cognitive impairment, in those satisfying core clinical criteria for possible AD because of unclear clinical presentation, and in patients with progressive dementia and atypically early age of onset. The committee recommends against imaging in asymptomatic individuals and patients with a clear AD diagnosis with typical age of onset. Scanning cannot be used to stage dementia or determine its severity, and it should not be used in lieu of genotyping for suspected autosomal mutation carriers. [86]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!